Abstract
Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Volume: 8 Issue: 3
Author(s): G. A. Cabral and L. Griffin-Thomas
Affiliation:
Keywords: Alzheimer's, amyotrophic lateral sclerosis, cannabinoids, cannabinoid receptors, granulomatous amebic encephalitis, HIV encephalitis, multiple sclerosis, neuroinflammation
Abstract: Cannabinoids have been reported to alter the activities of immune cells in vitro and in vivo. These compounds may serve as ideal agents for adjunct treatment of pathological processes that have a neuroinflammatory component. As highly lipophilic molecules, they readily access the brain. Furthermore, they have relatively low toxicity and can be engineered to selectively target cannabinoid receptors. To date, two cannabinoid receptors have been identified, characterized and designated CB1 and CB2. CB1 appears to be constitutively expressed within the CNS while CB2 apparently is induced during inflammation. The inducible nature of expression of CB2 extends to microglia, the resident macrophages of the brain that play a critical role during early stages of inflammation in that compartment. Thus, the cannabinoid-cannabinoid receptor system may prove therapeutically manageable in ablating neuropathogenic disorders such as Alzheimers disease, multiple sclerosis, amyotrophic lateral sclerosis, HIV encephalitis, closed head injury, and granulomatous amebic encephalitis.
Export Options
About this article
Cite this article as:
Cabral A. G. and Griffin-Thomas L., Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187153008785700118
DOI https://dx.doi.org/10.2174/187153008785700118 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Virus Attachment and Entry Offer Numerous Targets for Antiviral Therapy
Current Pharmaceutical Design Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy AIDS-Defining Illnesses: A Comparison Between Before and After Commencement of Highly Active Antiretroviral Therapy (HAART)
Current HIV Research The Application of Micro-Analytical Techniques to Biomedical Analysis
Current Pharmaceutical Analysis Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders The Induction of Proinflammatory Cytokines in Response to Avian Influenza H5N1 Infections and their Role in Pathogenesis and the Enhancement of Virulence
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS
Letters in Drug Design & Discovery Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Current Diabetes Reviews Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Thiosemicarbazides: Updates on Antivirals Strategy
Mini-Reviews in Medicinal Chemistry <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Editorial [Hot Topic: Mechanisms of HIV-1 Latency Post HAART Treatment Area (Guest Editors: Lena Al-Harthi and Fatah Kashanchi)]
Current HIV Research Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)